India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030. Growth is driven by increasing R&D investments, government initiatives, and rising domestic healthcare demand
Foreign Institutional Investors (FIIs) increasing their holding stake in certain companies indicate a positive outlook on the company’s performance, management, and prospects, thereby leading to speculation of expected future growth and upcoming changes in the company.
Listed below are some of the Pharmaceutical stocks in which FII/FPI have increased their stake in Q1FY25
Shilpa Medicare
Shilpa Medicare Limited is engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations for both domestic and international markets.
With a market capitalization of Rs. 6,317 Crores, the shares of Shilpa Medicare Limited closed on Tuesday’s trade at Rs. 646.05 per share, down 1.22 percent from its previous day’s close price of Rs. 654.
In Q1FY25 the FII/FPI increased their holding in Shilpa Medicare Limited from 5.63 percent in Q4FY24 to 3.63 percent in Q1FY25 by purchasing an additional 3.45 percent stake
Its Revenue from Operations grew by 10.08 percent from Rs. 1,046 Crores in FY23 to Rs. 1,152 Crores in FY24, accompanied by a loss of Rs. 31 Crores to a profit of Rs. 32 Crores.
Gland Pharma
Gland Pharma Limited is engaged in the business of pharmaceutical research, development, manufacturing, and marketing of complex injectables with a strong presence in injectables, oncology, and ophthalmology segments.
With a market capitalization of Rs. 33,829 Crores, the shares of Gland Pharma Limited closed on Tuesday’s trade at Rs. 2,053.35 per share, up 2.63 percent from its previous day’s close price of Rs. 2,000.65.
Also read
In Q1FY25 the FII/FPI increased their holding in Gland Pharma Limited from 3.59 percent in Q4FY24 to 6.88 percent in Q1FY25 by purchasing an additional 3.29 percent stake
Its Revenue from Operations grew by 56 percent from Rs. 3,625 Crores in FY23 to Rs. 5,665 Crores in FY24, accompanied by profits of Rs. 781 Crores to Rs. 772 Crores.
Marksans Pharma
Marksans Pharma Limited is engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations across various therapeutic areas, such as pain management, cough and cold, cardiovascular, central nervous system, and many more.
With a market capitalization of Rs. 8,510 Crores, the shares of Marksans Pharma Limited closed on Tuesday’s trade at Rs. 187.80 per share, up 0.13 percent from its previous day’s close price of Rs. 187.55.
In Q1FY25 the FII/FPI increased their holding in Marksans Pharma Limited from 15.57 percent in Q4FY24 to 18.59 percent in Q1FY25 by purchasing an additional 3.02 percent stake
Its Revenue from Operations grew by 17.56 percent from Rs. 1,852 Crores in FY23 to Rs. 2,177 Crores in FY24, accompanied by profits of Rs. 265 Crores to Rs. 315 Crores.
Mankind Pharma
Mankind Pharma Limited is one of the leading players in the pharmaceutical industry, it is engaged in developing, manufacturing, and selling a diverse range of markets pharmaceutical formulations across various acute, and chronic therapeutic areas and several consumer healthcare products.
With a market capitalization of Rs. 84,714 Crores, the shares of Mankind Pharma Limited closed on Tuesday’s trade at Rs. 2,114.50 per share, down 1.55 percent from its previous day’s close price of Rs. 2,147.70.
In Q1FY25 the FII/FPI increased their holding in Mankind Pharma Limited from 9.87 percent in Q4FY24 to 11.58 percent in Q1FY25 by purchasing an additional 1.71 percent stake
Also read
Its Revenue from Operations grew by 14 percent from Rs. 8,127 Crores in FY23 to Rs. 9,265 Crores in FY24, accompanied by profits of Rs. 1,248 Crores to Rs. 1,823 Crores.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
